-The Hindu Irrespective of fuel costs, investing in a robust public transport system alone can save the day Whenever news about a fall in oil prices hits the headline, the first to cheer are car users. "I can save up to Rs. 2,700 every month now. That means I can put this money to better use elsewhere," a journalist-friend recently said with a sigh of relief when asked to respond to the...

-The Hindu Providing people with a modest basic income instead of subsidies would save public revenue With oil prices falling, it was perhaps a good time to fade out fuel subsidies. All subsidies are inefficient and distortionary, and most are regressive. The same could be said of costly public works schemes as well. By contrast, the debate on direct benefit transfers has moved into a more sensible phase, with the posturing criticism of...

-Down to Earth Employment guarantee, rural road and sanitation schemes among those likely to be affected The upcoming budget will see social sectors face huge cuts in funds. Ministries concerned with infrastructure works, on the other hand, will be given with more funds. These include ministries of shipping, road and transport, telecom and power. The Prime Minister's Office (PMO) has directed the Union Ministry of Finance to include these budget adjustments in the...

-The Times of India NEW DELHI: The drug price regulator has mandated companies to seek its approval for every new medicine, including combinations of existing ones, to ensure that consumers are not overcharged. According to the National Pharmaceutical Pricing Authority (NPPA) all innovative launches like new combinations of price-controlled medicines as well as those with changed strengths and dosages will be treated as 'new medicines'. The move is aimed at spanning the...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...